Showing posts with label zoledronic acid. Show all posts
Showing posts with label zoledronic acid. Show all posts
Monday, February 21, 2011
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CAL
Note: side effects
INTERPRETATION: ZA every 3 months is well tolerated and prevents rapid bone loss in premenopausal women that develop CIOF. Giving ZA with rather than 1 year after the start of adjuvant chemotherapy is the preferred sequence to prevent bone loss.
Subscribe to:
Posts
(
Atom
)
